1
|
Jung YL, Yang YJ, Shil A, Sarkar S, Ahn KH. Anticancer Prodrug Capable of Mitochondria-Targeting, Light-Triggered Release, and Fluorescence Monitoring. ACS APPLIED BIO MATERIALS 2024; 7:3991-3996. [PMID: 38835291 DOI: 10.1021/acsabm.4c00342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2024]
Abstract
Mitigating the adverse effects of anticancer agents requires innovative prodrug engineering. In this study, we showcase the potential of our o-quinone methide-based trigger-release-conjugation platform as a versatile tool for constructing advanced prodrug systems. Using this platform, we achieved the light-triggered release of an anticancer drug mechlorethamine, targeting mitochondrial DNA. The entire process was adeptly tracked through the emission of fluorescence signals, revealing notable effects across various cancer cell lines compared to a normal cell line. Exploring alternative cancer-associated triggers, including enzymes, and incorporating cancer/tumor-specific targeting elements could lead to effective prodrugs with reduced cytotoxicity.
Collapse
Affiliation(s)
- Yun Lim Jung
- Department of Chemistry, Pohang University of Science and Technology, Pohang 37673, South Korea
| | - Yun Jae Yang
- Department of Chemistry, Pohang University of Science and Technology, Pohang 37673, South Korea
| | - Anushree Shil
- Department of Chemistry, Pohang University of Science and Technology, Pohang 37673, South Korea
| | - Sourav Sarkar
- Department of Chemistry, Pohang University of Science and Technology, Pohang 37673, South Korea
| | - Kyo Han Ahn
- Department of Chemistry, Pohang University of Science and Technology, Pohang 37673, South Korea
| |
Collapse
|
2
|
Klemt I, Reshetnikov V, Dutta S, Bila G, Bilyy R, Cuartero IC, Hidalgo A, Wünsche A, Böhm M, Wondrak M, Kunz-Schughart LA, Tietze R, Beierlein F, Imhof P, Gensberger-Reigl S, Pischetsrieder M, Körber M, Jost T, Mokhir A. A concept of dual-responsive prodrugs based on oligomerization-controlled reactivity of ester groups: an improvement of cancer cells versus neutrophils selectivity of camptothecin. RSC Med Chem 2024; 15:1189-1197. [PMID: 38665843 PMCID: PMC11042170 DOI: 10.1039/d3md00609c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2023] [Accepted: 01/20/2024] [Indexed: 04/28/2024] Open
Abstract
Many known chemotherapeutic anticancer agents exhibit neutropenia as a dose-limiting side effect. In this paper we suggest a prodrug concept solving this problem for camptothecin (HO-cpt). The prodrug is programmed according to Boolean "AND" logic. In the absence of H2O2 (trigger T1), e.g. in the majority of normal cells, it exists as an inactive oligomer. In cancer cells and in primed neutrophils (high H2O2), the oligomer is disrupted forming intermediate (inactive) lipophilic cationic species. These are accumulated in mitochondria (Mit) of cancer cells, where they are activated by hydrolysis at mitochondrial pH 8 (trigger T2) with formation of camptothecin. In contrast, the intermediates remain stable in neutrophils lacking Mit and therefore a source of T2. In this paper we demonstrated a proof-of-concept. Our prodrug exhibits antitumor activity both in vitro and in vivo, but is not toxic to normal cell and neutrophils in contrast to known single trigger prodrugs and the parent drug HO-cpt.
Collapse
Affiliation(s)
- Insa Klemt
- Department of Chemistry and Pharmacy, Organic Chemistry II, Friedrich-Alexander-University of Erlangen-Nürnberg (FAU) 91058 Erlangen Germany
| | - Viktor Reshetnikov
- Department of Chemistry and Pharmacy, Organic Chemistry II, Friedrich-Alexander-University of Erlangen-Nürnberg (FAU) 91058 Erlangen Germany
| | - Subrata Dutta
- Department of Chemistry and Pharmacy, Organic Chemistry II, Friedrich-Alexander-University of Erlangen-Nürnberg (FAU) 91058 Erlangen Germany
| | - Galyna Bila
- Department of Histology, Cytology and Embryology, Danylo Halytsky Lviv National Medical University 79010 Lviv Ukraine
| | - Rostyslav Bilyy
- Department of Histology, Cytology and Embryology, Danylo Halytsky Lviv National Medical University 79010 Lviv Ukraine
| | - Itziar Cossío Cuartero
- Program of Cardiovascular Regeneration, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) C. Melchor Fernández Almagro, 3 28029 Madrid Spain
| | - Andrés Hidalgo
- Program of Cardiovascular Regeneration, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) C. Melchor Fernández Almagro, 3 28029 Madrid Spain
| | - Adrian Wünsche
- Department of Chemistry and Pharmacy, Organic Chemistry II, Friedrich-Alexander-University of Erlangen-Nürnberg (FAU) 91058 Erlangen Germany
| | - Maximilian Böhm
- Department of Chemistry and Pharmacy, Organic Chemistry II, Friedrich-Alexander-University of Erlangen-Nürnberg (FAU) 91058 Erlangen Germany
| | - Marit Wondrak
- OncoRay, National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden and Helmholtz-Zentrum Dresden-Rossendorf Dresden Germany
| | - Leoni A Kunz-Schughart
- OncoRay, National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden and Helmholtz-Zentrum Dresden-Rossendorf Dresden Germany
- National Center for Tumor Diseases (NCT) Partner Site Dresden Germany
| | - Rainer Tietze
- Department of Otorhinolaryngology, Head and Neck Surgery, Section of Experimental Oncology and Nanomedicine (SEON), FAU University Hospital 91054 Erlangen Germany
| | - Frank Beierlein
- Erlangen National High Performance Computing Center (NHR@FAU), FAU 91058 Erlangen Germany
- Computer-Chemistry-Center, Department of Chemistry and Pharmacy, FAU Germany
| | - Petra Imhof
- Erlangen National High Performance Computing Center (NHR@FAU), FAU 91058 Erlangen Germany
- Computer-Chemistry-Center, Department of Chemistry and Pharmacy, FAU Germany
| | | | | | - Marlies Körber
- Department of Chemistry and Pharmacy, Organic Chemistry II, Friedrich-Alexander-University of Erlangen-Nürnberg (FAU) 91058 Erlangen Germany
| | - Tina Jost
- Department of Radiation Oncology, FAU University Hospital 91054 Erlangen Germany
| | - Andriy Mokhir
- Department of Chemistry and Pharmacy, Organic Chemistry II, Friedrich-Alexander-University of Erlangen-Nürnberg (FAU) 91058 Erlangen Germany
| |
Collapse
|
3
|
Shaw PA, Klausen M, Bradley M. A dual action coumarin-camptothecin polymer for light responsive drug release and photodynamic therapy. Polym Chem 2024; 15:54-58. [PMID: 38174055 PMCID: PMC10758926 DOI: 10.1039/d3py01137b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Accepted: 12/04/2023] [Indexed: 01/05/2024]
Abstract
A light-responsive polymer allowing the controlled release of camptothecin and the generation of reactive oxygen species (ROS) is reported. The polymer was prepared by controlled copolymerisation of water-soluble N,N-dimethyl acrylamide with a bromocoumarin methacrylate monomer. The lipophilic chemotherapy agent camptothecin was caged onto the coumarin unit via a photo-cleavable carbonate ester enabling light-triggered cargo release. The polymer showed good biocompatibility in the dark, and high cancer cell killing activity mediated both by the photo-release of camptothecin and ROS generation.
Collapse
Affiliation(s)
- Paige A Shaw
- EaStCHEM School of Chemistry, University of Edinburgh David Brewster Road EH9 3FJ Edinburgh UK
| | - Maxime Klausen
- EaStCHEM School of Chemistry, University of Edinburgh David Brewster Road EH9 3FJ Edinburgh UK
- Department of Materials, Department of Bioengineering, and Institute of Biomedical Engineering, Imperial College London London SW7 2AZ UK
| | - Mark Bradley
- EaStCHEM School of Chemistry, University of Edinburgh David Brewster Road EH9 3FJ Edinburgh UK
- Precision Healthcare University Research Institute, Queen Mary University of London Empire House London E1 1HH UK
| |
Collapse
|